Optimism in Gene Therapy Development

This chapter explores the hopeful outlook of pharmaceutical leaders regarding the Trump administration amidst industry cuts, and highlights Solid Biosciences' promising advancements in gene therapy for Duchenne muscular dystrophy. It reflects on the company's resilience through past challenges while navigating a competitive landscape for effective treatment options.